{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Severe adverse events were defined as grade 3 or higher, at least possibly related to study drugs. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.","groups":[{"description":"Lenalidomide (Len) 15mg daily (days 1-21); Cyclophosphamide (Cyc) 300 mg/m\\^2 (days 1, 8, 15); Dexamethasone (Dex) 40 mg weekly","id":"OG000","title":"Len/Cyc/Dex"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 3 years)","title":"Number of Participants With Severe Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}